Fact checked byChristine Klimanskis, ELS
October 11, 2022
1 min read
Save

Retinitis pigmentosa treatment receives fast track designation

Fact checked byChristine Klimanskis, ELS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted fast track designation to MCO-010 from Nanoscope Therapeutics for the treatment of retinitis pigmentosa.

The ambient light activatable multi-characteristic opsin optogenetic monotherapy is administered by intravitreal injection to patients with retinitis pigmentosa who have advanced vision loss. Topline data from the RESTORE clinical trial of MCO-010 in 27 patients with retinitis pigmentosa are expected in the first half of 2023.

FDA-sign_323811316
Source: Adobe Stock

In addition, Nanoscope recently completed enrollment in the phase 2 STARLIGHT clinical trial of MCO-010 in patients with advanced vision loss due to Stargardt disease. Six-month data are expected in the first half of 2023.

“The FDA’s decision to grant [fast track designation] underscores the importance of MCO-010 to address a serious unmet need and validates its potential as an effective therapeutic for patients with [retinitis pigmentosa],” Sulagna Bhattacharya, CEO of Nanoscope, said in a press release. “We are proud to have the support of the FDA and look forward to collaboratively interacting with FDA to assess next steps in the clinical development and future regulatory review of MCO-010.”